Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

Damiano Paolicelli, Vita Direnzo, Maria TrojanoDepartment of Neurological and Psychiatric Sciences, University of Bari, Bari, ItalyAbstract: Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Damiano Paolicelli, Vita Direnzo, Maria Trojano
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2c29e7f5c1254fe1969becb677ec4d26
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c29e7f5c1254fe1969becb677ec4d26
record_format	dspace
spelling	oai:doaj.org-article:2c29e7f5c1254fe1969becb677ec4d262021-12-02T06:05:19ZReview of interferon beta-1b in the treatment of early and relapsing multiple sclerosis1177-54751177-5491https://doaj.org/article/2c29e7f5c1254fe1969becb677ec4d262009-07-01T00:00:00Zhttp://www.dovepress.com/review-of-interferon-beta-1b-in-the-treatment-of-early-and-relapsing-m-a3349https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Damiano Paolicelli, Vita Direnzo, Maria TrojanoDepartment of Neurological and Psychiatric Sciences, University of Bari, Bari, ItalyAbstract: Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFN&beta;)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFN&beta;-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFN&beta;-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFN&beta;-1b was administered to still-active secondary progressive MS. IFN&beta;-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFN&beta;-1b still remains a first-line therapy with a fundamental role in all stages of the disease.Keywords: interferon beta-1b, relapsing-remitting multiple sclerosis, clinically isolated syndromes, efficacy, safety, neutralizing antibodies Damiano PaolicelliVita DirenzoMaria TrojanoDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 369-376 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Damiano Paolicelli Vita Direnzo Maria Trojano Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
description	Damiano Paolicelli, Vita Direnzo, Maria TrojanoDepartment of Neurological and Psychiatric Sciences, University of Bari, Bari, ItalyAbstract: Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFN&beta;)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFN&beta;-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFN&beta;-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFN&beta;-1b was administered to still-active secondary progressive MS. IFN&beta;-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFN&beta;-1b still remains a first-line therapy with a fundamental role in all stages of the disease.Keywords: interferon beta-1b, relapsing-remitting multiple sclerosis, clinically isolated syndromes, efficacy, safety, neutralizing antibodies
format	article
author	Damiano Paolicelli Vita Direnzo Maria Trojano
author_facet	Damiano Paolicelli Vita Direnzo Maria Trojano
author_sort	Damiano Paolicelli
title	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
title_short	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
title_full	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
title_fullStr	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
title_full_unstemmed	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
title_sort	review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/2c29e7f5c1254fe1969becb677ec4d26
work_keys_str_mv	AT damianopaolicelli reviewofinterferonbeta1binthetreatmentofearlyandrelapsingmultiplesclerosis AT vitadirenzo reviewofinterferonbeta1binthetreatmentofearlyandrelapsingmultiplesclerosis AT mariatrojano reviewofinterferonbeta1binthetreatmentofearlyandrelapsingmultiplesclerosis
_version_	1718400041978167296

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

Ejemplares similares